Phase III trial shows improved response rates and overall survival in acute lymphoblastic leukemia, suggesting a shift in standard of care.
In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy–imatinib regimen for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: